ReviewJournal of cellular and molecular medicine2013
Toll-like receptors in prostate infection and cancer between bench and bedside.
Review in Journal of cellular and molecular medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Inflammatory response to Trichomonas vaginalis in the pathogenesis of prostatitis and benign prostatic hyperplasia.Parasites, hosts and diseases · 2023Review
- Interleukin-1 receptor associated kinase 1 (IRAK1) is epigenetically activated in luminal epithelial cells in prostate cancer.Frontiers in oncology · 2022Article
- Inflammation-Induced Tumorigenesis and Metastasis.International journal of molecular sciences · 2021Review
- Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility.BioMed research international · 2021Review
- Network Pharmacology-Based Study on the Mechanism of Gegen Qinlian Decoction against Colorectal Cancer.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- Increased Preoperative Plasma Level of Microbial 16S rDNA Translocation Is Associated With Relapse After Prostatectomy in Prostate Cancer Patients.Frontiers in oncology · 2019Article
- Stem-like and highly invasive prostate cancer cells expressing CD44v8-10 marker originate from CD44-negative cells.Oncotarget · 2018Article
- Immune profiling of human prostate epithelial cells determined by expression of p38/TRAF-6/ERK MAP kinases pathways.The Kaohsiung journal of medical sciences · 2018Article
- The Pathologic Role of Toll-Like Receptor 4 in Prostate Cancer.Frontiers in immunology · 2018Review
- The inflammatory microenvironment and microbiome in prostate cancer development.Nature reviews. Urology · 2018Review
- Toll-like receptor expression in human non-small cell lung carcinoma: potential prognostic indicators of disease.Oncotarget · 2017Article
- Expression analysis of inflammasome sensors and implication of NLRP12 inflammasome in prostate cancer.Scientific reports · 2017Article
- Multifunctional Polymer Nanoparticles for Dual Drug Release and Cancer Cell Targeting.Polymers · 2017Article
- Review
- The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.Biomarkers in cancer · 2016Review
- Expression and Polymorphism of Toll-Like Receptor 4 and Effect on NF-κB Mediated Inflammation in Colon Cancer Patients.PloS one · 2016Article
- TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo.Journal of cellular and molecular medicine · 2015Article
- Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy.World journal of gastroenterology · 2014Review
- The same and not the same: heterogeneous functional activation of prostate tumor cells by TLR ligation.Cancer cell international · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Toll-Like receptors (TLRs) are a family of evolutionary conserved transmembrane proteins that recognize highly conserved molecules in pathogens. TLR-expressing cells represent the first line of defence sensing pathogen invasion, triggering innate immune responses and subsequently priming antigen-specific adaptive immunity. In vitro and in vivo studies on experimental cancer models have shown both anti- and pro-tumoural activity of different TLRs in prostate cancer, indicating these receptors as potential targets for cancer therapy. In this review, we highlight the intriguing duplicity of TLR stimulation by pathogens: their protective role in cases of acute infections, and conversely their negative role in favouring hyperplasia and/or cancer onset, in cases of chronic infections. This review focuses on the role of TLRs in the pathophysiology of prostate infection and cancer by exploring the biological bases of the strict relation between TLRs and prostate cancer. In particular, we highlight the debated question of how reliable mutations or deregulated expression of TLRs are as novel diagnostic or prognostic tools for prostate cancer. So far, the anticancer activity of numerous TLR ligands has been evaluated in clinical trials only in organs other than the prostate. Here we review recent clinical trials based on the most promising TLR agonists in oncology, envisaging a potential application also in prostate cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.